[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562070":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":30,"responsibleParty":35,"collaborators":30,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":30,"eligibilityCriteria":43,"healthyVolunteers":39,"sex":44,"minAge":45,"maxAge":30,"enrollmentInfo":46,"targetDuration":30,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":30,"overallStatus":55,"whyStopped":30,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":30},{"fullName":5,"class":6},"Navy General Hospital, Beijing","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Venetoclax combined with Azacytidine","EXPERIMENTAL","Patients were treated by venetoclax and azacytidine",[13],"Drug: Venetoclax combined with Azacytidine",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Patients were treated by venetoclax and azacytidine:\n\nVenetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-7; Azacytidine 75 mg\u002Fm2 subcutaneous injection qd d1-5.",[9],[20],"VA",[22],{"name":23,"affiliation":5,"role":24},"Liren Qian","PRINCIPAL_INVESTIGATOR",[26,32],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Liren Qian, PhD","CONTACT","+861066947194",null,"qlr2007@126.com",{"name":33,"role":28,"phone":34,"phoneExt":30,"email":30},"Yu Liu, PhD","+861066947192",{"type":24,"investigatorFullName":23,"investigatorTitle":36,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"Vice Director","100562070","phase-2-va-as-maintenance-therapy-post-allo-hsct-in-mds-and-aml-100562070",false,"NCT06598384","VA as Maintenance Therapy Post Allo-HSCT in MDS and AML","Venetoclax Combined With Azacytidine as Maintenance Therapy Post Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndromes and Acute Myeloid Leukemia","Inclusion Criteria:\n\n* The patient should, in the investigator's opinion, be able to meet all clinical trial requirements.\n* The patient is willing and able to adhere to the study visit schedule and other protocol requirements.\n* Patients aged ≥18 years with a diagnosis of MDS or AML according to World Health Organization criteria (WHO) who had undergone alloSCT with myeloablative or reduced-intensity conditioning regimens were eligible. Related and unrelated donors were permitted.\n* Patients should be in morphologic complete remission (CR; ie, ≤5% bone marrow blasts) with absolute neutrophil counts ≥1.0×10\\^9 \u002FL and platelets ≥ 75×10\\^ 9 \u002FL before treatment.\n\nExclusion Criteria:\n\n* Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment.\n* Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.\n* Pregnant or lactating women.","ALL","16 Years",{"count":47,"type":48},40,"ESTIMATED","INTERVENTIONAL",[51],"PHASE2","The goal of this phase 2 trial is to test the safety and efficacy of Venetoclax combined with Azacytidine as Maintenance Therapy post Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndromes and Acute Myeloid Leukemia.",[54],"Acute Myeloid Leukemia","NOT_YET_RECRUITING","2024-09-28",{"date":58,"type":59},"2024-10-01","ACTUAL",{"date":61,"type":48},"2024-09",{"date":63,"type":48},"2030-09",{"name":5,"class":6}]